neve-header

Thomas Glanzmann is a healthcare executive, investor, and board director whose career spans medical technologies, diagnostics, biotechnology, and biopharmaceuticals. He is a Partner and venture capital investor with Medtech Ventures Partners, which he co-founded in 2017.

Thomas most recently held a series of senior leadership roles at Grifols S.A., including Chief Executive Officer, Executive Chairman, and Non-Executive Chairman, having served on the company’s Board since 2006. Previously, he was President and Chief Executive Officer of Gambro AB and Chief Executive Officer and Managing Director of HemoCue AB. He also spent more than 15 years at Baxter International, including as President of Baxter Bioscience, and later served as Senior Advisor to the Executive Chairman and a Managing Director of the World Economic Forum.

Thomas currently serves on the boards of Alcon and Swiss Steel. His board experience spans public, private equity-backed, and privately held companies.

Thomas holds a BS in Political Science from Dartmouth College, an MBA from IMD Business School, and a Board of Directors Certification from the UCLA Anderson School of Management.

John Young is a global healthcare leader whose 35-year career at Pfizer included a decade on the company’s Executive Leadership Team. He served as Global President of Primary Care and the Pfizer Essential Health business unit and, beginning in 2019, as Chief Business Officer. In 2020, he chaired Pfizer’s COVID SWAT Team.

John began his career with Pfizer as a trainee in his native Scotland in 1987, progressing through sales, marketing, and general management roles before becoming Regional President for Europe, Canada, Australia and New Zealand in 2009.

John currently serves on the boards of Novartis AG and Johnson Controls International. He previously served on the UK Government’s Life Sciences Council and the boards of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Biotechnology Innovation Organization (BIO).

John holds a BSc in Biological Sciences from the University of Glasgow and an MBA from Strathclyde Graduate Business School.

Alan Eustace is a computer scientist and engineer who spent 13 years in senior leadership at Google. Joining the company in 2002, he served as Senior Vice President of Engineering from 2005 to 2012, and subsequently as Senior Vice President of Knowledge until his retirement in 2015. In these roles, he led Google’s global engineering and research efforts, overseeing the technical infrastructure and product development that scaled the company’s core services to billions of users.

Prior to Google, Alan spent 15 years at Digital/Compaq/HP’s Western Research Laboratory, where he directed research in high-performance computing and chip architecture. He is a co-inventor on 10 patents and co-developed ATOM, a foundational system for binary-code instrumentation. Beyond his corporate leadership, Alan is a world-record-holding explorer; in 2014, he led the StratEx mission, successfully completing a record-breaking free-fall jump from the stratosphere at 135,890 feet.

Alan holds a Ph.D. in Computer Science from the University of Central Florida. He currently serves on the boards of the Commonwealth Fusion Systems, Pivotal, and Urban Sky.

Suzanne Nora Johnson is a business and philanthropic leader who has served at the highest levels of major nonprofit and corporate organizations. She is Chair of the University of Southern California Board of Trustees, a member of the Pfizer, Inc. Board of Directors, and former Member, Lead Independent Director, and Chair of the Intuit, Inc. Board of Directors.

Previously, Suzanne was Vice Chairman of The Goldman Sachs Group, Inc., where she served as Chairman of the Global Markets Institute and was a member of the firm’s Management Committee. Prior to joining Goldman Sachs, she was an attorney with Simpson, Thacher & Bartlett and a law clerk for the U.S. Court of Appeals.

She serves on the boards of several nonprofit institutions, including the Brookings Institution (Co-Chair) and the Markle Foundation (Chair), America’s Frontier Fund, and The Broad Foundation. She is a member of the American Academy of the Arts and Sciences (Chair of the Investment Committee), the Council on Foreign Relations, and Foreign Policy Association. She has also served as chair and member of various Global Agenda Councils for the World Economic Forum and was a Henry Crown Fellow at the Aspen Institute.

Suzanne received her J.D. from Harvard Law School and her B.A. from the University of Southern California.

Judy is a physician scientist widely known in the field of molecular cardiology, and pioneered the use of transgenic animals to understand cardiovascular development and disease. 

She has served as Chair of the Department of Medicine at Stanford University, Dean for Translational Medicine at the University of California, San Diego as well as Director of Cardiovascular Medicine at the University of Pennsylvania. She is currently Chair of the Scientific Advisory Board for the Wyss Institute for Biologically Inspired Engineering at Harvard University. 

Judy has held several national leadership roles, including President of the American Association of Physicians, President of the American Society of Clinical Investigation, and an elected member of the Council of the National Academy of Medicine. 

Judy is currently the Chief Medical Officer of Physiowave, LLC and has served as a Director / Science advisor to several biotech and pharmaceutical companies. She is the recipient of the Singapore Presidential Science and Technology Medal, the highest scientific award bestowed in Singapore.

Richard Gillingwater is currently the Chair of SSE, the renewable energy and networks group, and Janus Henderson, a global asset manager. After a career in finance, he set up and ran UK Government Investments, created to manage the Government’s state-owned businesses, and chaired the UK’s development finance business, CDC, investing in Africa and Asia. He has also served as Dean of Cass Business School and as Chair of the Open University and has wide board experience.

Gillingwater has a law degree from Oxford University, and an MBA from IMD Lausanne.

John-Arne Røttingen is Chief Executive Officer of Wellcome, UK. He has served as Ambassador for Global Health at the Ministry of Foreign Affairs, Norway, been Adjunct Scientific Director at the Norwegian Institute of Public Health and Visiting Fellow of Practice at Blavatnik School of Government, Oxford University. He was the founding Chief Executive Officer of CEPI – Coalition for Epidemic Preparedness Innovations and has been the Chief Executive of the Research Council of Norway; Executive Director of Infection Control and Environmental Health at the Norwegian Institute of Public Health; Professor of Health Policy at the Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo; and Adjunct Professor at the Department of Global Health and Population, Harvard T.H. Chan School of Public Health.

He is member of the Norwegian Academy of Science and Letters and international member of the US National Academy of Medicine. He received his MD and PhD from the University of Oslo, an MSc from Oxford University and an MPA from Harvard University, and was awarded H.M. the King’s Gold Medal for his doctoral dissertation.

Paul Schreier was appointed Wellcome’s Interim Chief Executive Officer in February 2023. He joined the Wellcome Trust as Chief Operating Officer in 2019, responsible for Wellcome’s internal and international operations. He is also a member of the investment committee that oversees Wellcome’s investments’ activities.

Paul was born in Australia and came to the UK for university, taking his BA, Master’s and PhD degrees in engineering at Cambridge before joining the Royal Navy, subsequently serving as a navigator and fighter controller. After commanding a ship, he left to join McKinsey & Company’s London office, where he became a partner before moving to Kuala Lumpur. In 2010, he was appointed to the Australian Department of the Prime Minister and Cabinet, becoming deputy secretary with responsibility for economic policy and strategy.

Later, he served as deputy vice-chancellor and chief operating officer at Macquarie University in Sydney, before joining Hakluyt, a professional services firm, in 2016 as chief executive.

He is a member of the Council of the National Army Museum in London, and is on the board of the Francis Crick Institute in London, and the Sanger Institute near Cambridge.